- Home
- HPE vs ILMN Comparison
HPE vs ILMN Comparison
Compare HPE & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HPE | ILMN |
|---|---|---|
| Founded | 1939 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.5B | 20.5B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | HPE | ILMN |
|---|---|---|
| Price | $23.99 | $133.59 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 18 | 16 |
| Target Price | $26.13 | ★ $117.31 |
| AVG Volume (30 Days) | ★ 25.9M | 1.5M |
| Earning Date | 12-04-2025 | 02-05-2026 |
| Dividend Yield | ★ 2.37% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 4.46 |
| Revenue | ★ $34,296,000,000.00 | $4,288,000,000.00 |
| Revenue This Year | $20.20 | N/A |
| Revenue Next Year | $5.84 | $2.24 |
| P/E Ratio | ★ N/A | $29.40 |
| Revenue Growth | ★ 13.84 | N/A |
| 52 Week Low | $11.97 | $68.70 |
| 52 Week High | $26.44 | $153.06 |
Technical Indicators
Market Signals| Indicator | HPE | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 52.57 | 55.28 |
| Support Level | $23.39 | $132.93 |
| Resistance Level | $24.80 | $135.95 |
| Average True Range (ATR) | 0.51 | 3.28 |
| MACD | -0.06 | -0.94 |
| Stochastic Oscillator | 42.76 | 35.28 |
Price Performance
Historical ComparisonAbout HPE Hewlett Packard Enterprise Company
Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment; it also has a high-performance computing business. HPE's stated goal is to be a complete edge-to-cloud company. Its portfolio enables hybrid clouds and hyperconverged infrastructure.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.